Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3992021 | Journal of Thoracic Oncology | 2008 | 4 Pages |
Abstract
Inflammation is an important contributor to lung tumor development and progression. In addition, inflammatory signaling may promote epithelial to mesenchymal transition, development of aggressive metastatic tumor phenotypes, and play a role in resistance to targeted therapies. New insights in inflammatory signaling have led to the evaluation of combination therapies that target these specific pathways. In addition to developing the optimal combination of targeted agents, biomarker-based selection of patients who will likely benefit will be critical to the success of this strategy. Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Kostyantyn Krysan, Jay M. Lee, Mariam Dohadwala, Brian K. Gardner, Karen L. Reckamp, Edward Garon, Maie St. John, Sherven Sharma, Steven M. Dubinett,